163,021 Shares in Capricor Therapeutics, Inc. $CAPR Acquired by Jump Financial LLC

Key Points

• Jump Financial LLC has taken a new position in Capricor Therapeutics, purchasing 163,021 shares valued at approximately $1.55 million, which accounts for 0.36% of the company.
• Capricor Therapeutics has a market cap of $286.21 million and has experienced significant price fluctuations with a 1-year low of $3.98 and a 1-year high of $23.40.
• Despite some analysts issuing "buy" ratings, Capricor's recent earnings report showed a loss of $0.57 per share, missing the consensus estimate by $0.09.

Jump Financial LLC acquired a new position in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 163,021 shares of the biotechnology company's stock, valued at approximately $1,547,000. Jump Financial LLC owned approximately 0.36% of Capricor Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Citizens Financial Group Inc. RI purchased a new stake in Capricor Therapeutics in the first quarter valued at approximately $95,000. Arizona State Retirement System purchased a new stake in shares of Capricor Therapeutics during the 1st quarter valued at $111,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Capricor Therapeutics by 31.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,246 shares of the biotechnology company's stock valued at $126,000 after buying an additional 3,162 shares in the last quarter. ProShare Advisors LLC bought a new stake in shares of Capricor Therapeutics during the 4th quarter worth $142,000. Finally, Voya Investment Management LLC purchased a new position in Capricor Therapeutics in the fourth quarter worth $150,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock traded up $0.03 during mid-day trading on Wednesday, reaching $6.36. 122,951 shares of the stock traded hands, compared to its average volume of 1,968,468. The business's 50-day moving average is $8.00 and its 200-day moving average is $10.30. The stock has a market capitalization of $290.76 million, a PE ratio of -3.88 and a beta of 0.73. Capricor Therapeutics, Inc. has a 12-month low of $3.98 and a 12-month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%. Equities analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on CAPR. Jones Trading cut their price objective on Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating for the company in a report on Wednesday, June 25th. Roth Capital cut their price target on shares of Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating on the stock in a report on Monday, July 14th. B. Riley assumed coverage on shares of Capricor Therapeutics in a report on Thursday, June 26th. They set a "buy" rating and a $21.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Finally, Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $22.56.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.